このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

局所進行性または転移性固形腫瘍(六価OX40アゴニスト)を有する被験者におけるペムブロリズマブと組み合わせたINBRX-106およびINBRX-106の研究

2026年11月4日 更新者:Inhibrx Biosciences, Inc

局所進行性または転移性固形腫瘍の被験者を対象としたペムブロリズマブと組み合わせた INBRX-106 および INBRX-106 の非盲検、多施設共同、ヒト初、用量漸増、第 1 相試験

This is a Phase 1/2, open-label, non-randomized, 4-part trial to determine the safety profile and identify the maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D) of INBRX 106 administered as a single agent or in combination with the anti-PD-1 checkpoint inhibitor (CPI) pembrolizumab (Keytruda®). KEYTRUDA is a registered trademark of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA.

調査の概要

研究の種類

介入

入学 (推定)

340

段階

  • フェーズ2
  • フェーズ 1

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究連絡先

研究場所

    • California
      • Duarte、California、アメリカ、91010
        • 積極的、募集していない
        • City of Hope
      • Glendale、California、アメリカ、91204
        • 募集
        • Oncura Health
        • コンタクト:
        • 主任研究者:
          • Sungwon Kyung, MD
      • La Jolla、California、アメリカ、92037
        • まだ募集していません
        • UC San Diego Health - Moores Cancer Center
        • 主任研究者:
          • Lyudmila Bazhenova, MD
      • Los Angeles、California、アメリカ、90027
        • 募集
        • California Research Institute
        • 主任研究者:
          • Ghassan Al-Jazayrly, MD
        • コンタクト:
      • Los Angeles、California、アメリカ、90069
      • Los Angeles、California、アメリカ、90033
        • まだ募集していません
        • University of Southern California Norris Comprehensive Cancer Center
        • 主任研究者:
          • Jorge Nieva, MD
      • Murrieta、California、アメリカ、92562
        • 募集
        • Valkyrie Clinical Trials
        • 主任研究者:
          • David Berz, MD
        • コンタクト:
      • Santa Rosa、California、アメリカ、95403
        • 募集
        • Providence Medical Foundation
        • 主任研究者:
          • Ian Anderson, MD
        • コンタクト:
    • Colorado
      • Lakewood、Colorado、アメリカ、80228
        • まだ募集していません
        • Valkyrie Clinical Trials - Colorado
        • 主任研究者:
          • Jason Henry, MD
    • Florida
      • Clermont、Florida、アメリカ、34711
        • 募集
        • Clermont Oncology Center
        • 主任研究者:
          • Gopal Kunta, MD
        • コンタクト:
      • Orange City、Florida、アメリカ、32763
        • 募集
        • Mid Florida Hematology and Oncology Center
        • 主任研究者:
          • Santosh Nair, MD
        • コンタクト:
    • Georgia
      • Atlanta、Georgia、アメリカ、30322
        • 積極的、募集していない
        • Winship Cancer Institute - Emory University
    • Illinois
      • Chicago、Illinois、アメリカ、60612
        • まだ募集していません
        • University of Illinois Cancer Center
        • 主任研究者:
          • Frank Weinberg, MD, PhD
      • Chicago、Illinois、アメリカ、60637
        • 積極的、募集していない
        • The University of Chicago Medical Center
    • Iowa
      • Iowa City、Iowa、アメリカ、52242
        • 募集
        • University of Iowa
        • 主任研究者:
          • Douglas Laux, MD
        • コンタクト:
    • Kentucky
      • Louisville、Kentucky、アメリカ、40202
    • Michigan
      • Detroit、Michigan、アメリカ、48202
        • 募集
        • Henry Ford Cancer Institute
        • 主任研究者:
          • Amy Weise, MD
        • コンタクト:
      • Detroit、Michigan、アメリカ、48201
        • 完了
        • Barbara Ann Karmanos Cancer Institute
      • Grand Rapids、Michigan、アメリカ、49546
        • 積極的、募集していない
        • START Midwest
    • Minnesota
      • Saint Louis Park、Minnesota、アメリカ、55426
        • 積極的、募集していない
        • HealthPartners Cancer Research Center
      • Saint Paul、Minnesota、アメリカ、55101
        • 完了
        • HealthPartners Cancer Research Center (Regions Hospital)
    • Missouri
      • St Louis、Missouri、アメリカ、63110
        • まだ募集していません
        • Washington University in St. Louis School of Medicine
        • 主任研究者:
          • Brett Herzog, MD, PhD
    • Montana
      • Billings、Montana、アメリカ、59102
        • 完了
        • Intermountain Health Cancer Centers of Montana
    • Nebraska
      • Grand Island、Nebraska、アメリカ、68803
        • まだ募集していません
        • Nebraska Cancer Specialists - Grand Island
        • 主任研究者:
          • Ralph Hauke, MD
      • Omaha、Nebraska、アメリカ、68130
        • 募集
        • Nebraska Cancer Specialists
        • 主任研究者:
          • Ralph Hauke, MD
        • コンタクト:
    • New Jersey
      • Camden、New Jersey、アメリカ、08103
        • まだ募集していません
        • MD Anderson Cancer Center at Cooper
        • 主任研究者:
          • Polina Khrizman, MD
    • New York
      • The Bronx、New York、アメリカ、10467
        • 積極的、募集していない
        • Montefiore Medical Center
    • Ohio
      • Cleveland、Ohio、アメリカ、44195
        • 積極的、募集していない
        • Cleveland Clinic
    • Oregon
      • Portland、Oregon、アメリカ、97213
        • 積極的、募集していない
        • Providence Portland Medical Center
    • Pennsylvania
      • Allentown、Pennsylvania、アメリカ、18103
        • まだ募集していません
        • Lehigh Valley Health Network
        • 主任研究者:
          • Muhammad Rizvi, MD
    • Tennessee
      • Knoxville、Tennessee、アメリカ、37923
        • まだ募集していません
        • University of Tennessee Health Science Center
        • 主任研究者:
          • Sean Jordan, MD
      • Nashville、Tennessee、アメリカ、37204
        • 積極的、募集していない
        • Vanderbilt University School of Medicine
    • Texas
      • Dallas、Texas、アメリカ、75230
        • 完了
        • Sarah Cannon Research Institute at Mary Crowley
      • El Paso、Texas、アメリカ、79915
        • 完了
        • Renovatio Clinical - El Paso
      • San Antonio、Texas、アメリカ、78229
        • 完了
        • NEXT Oncology
      • The Woodlands、Texas、アメリカ、77380
        • 完了
        • Renovatio Clinical
      • Tyler、Texas、アメリカ、75701
        • 募集
        • The University of Texas Health Science Center at Tyler
        • コンタクト:
        • 主任研究者:
          • Erminia Massarelli, MD, PhD, MS
    • Virginia
      • Fairfax、Virginia、アメリカ、22031
        • 完了
        • Virginia Cancer Specialists
    • Wisconsin
      • Milwaukee、Wisconsin、アメリカ、53226
        • 募集
        • Froedtert Hospital and the Medical College of Wisconsin
        • 主任研究者:
          • Jonathan Thompson, MD
        • コンタクト:
      • Singapore、シンガポール
        • 完了
        • Curie Oncology
      • Singapore、シンガポール
        • 完了
        • Icon Cancer Centre Farrer Park
      • Singapore、シンガポール
        • 完了
        • Icon Cancer Centre Mount Alvernia
      • Changhua、台湾
        • 積極的、募集していない
        • Changhua Christian Hospital (CCH)
      • Kaohsiung City、台湾
        • 積極的、募集していない
        • E-Da Cancer Hospital
      • Kaohsiung City、台湾
        • 積極的、募集していない
        • Kaohsiung Medical University Chung-Ho Memorial Hospital (KMUH)
      • Tainan、台湾
        • 積極的、募集していない
        • National Cheng Kung University Hospital
      • Taipei、台湾
        • 完了
        • Taipei Veterans General Hospital
      • Busan、韓国
        • まだ募集していません
        • Inje University College of Medicine
        • 主任研究者:
          • IL-Hwan Kim, MD, PhD
      • Cheongju-si、韓国
        • まだ募集していません
        • Chungbuk National University Hospital
        • 主任研究者:
          • Ki-Hyeong Lee, MD
      • Gyeonggi-do、韓国
        • 募集
        • The Catholic University of Korea, St. Vincent's Hospital
        • 主任研究者:
          • Byoung Yong Shim
      • Hwasun、韓国
        • まだ募集していません
        • Chonnam National University Hwasun Hospital
        • 主任研究者:
          • In-Jae Oh, MD, MS, PhD
      • Incheon、韓国
        • まだ募集していません
        • Gachon University Gil Medical Center
        • 主任研究者:
          • Eun Kyung Cho, PhD, M.S
      • Seongnam-si、韓国
        • まだ募集していません
        • CHA Bundang Medical Center
        • 主任研究者:
          • Yoon Beom Sang
      • Seoul、韓国
        • 募集
        • Asan Medical Center
        • コンタクト:
        • 主任研究者:
          • Dae Ho Lee, MD
      • Seoul、韓国
        • 募集
        • Severance Hospital, Yonsei University Health System
        • コンタクト:
        • 主任研究者:
          • Sun Mun Lim
      • Seoul、韓国
        • 募集
        • The Catholic University of Korea Seoul St. Mary's Hospital,
        • 主任研究者:
          • SookHee Hong
        • コンタクト:
      • Seoul、韓国
        • まだ募集していません
        • Korea University Anam Hospital
        • 主任研究者:
          • Yoon Ji Choi, MD, MS, PhD
      • Seoul、韓国
        • まだ募集していません
        • Hanyang University Seoul Hospital
        • 主任研究者:
          • Myung- Ju Ahn, MD, PhD, MS
      • Seoul、韓国
        • まだ募集していません
        • Korea University Guro Hospital
        • 主任研究者:
          • Sung Yong Lee
        • 主任研究者:
          • Sung Yong Lee, MD, MS, PhD
      • Suwon、韓国
        • まだ募集していません
        • Ajou University Hospital
        • 主任研究者:
          • Yong-Won Choi, MD

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

18年歳以上 (大人、高齢者)

健康ボランティアの受け入れ

いいえ

受講資格のある性別

全て

説明

Select Inclusion Criteria:

  • Males or females aged ≥18 years.
  • Parts 1 and 3 (escalation cohorts): Subjects with locally advanced or metastatic non resectable solid tumors, whose disease has progressed despite all standard therapies or for whom no further standard or clinically acceptable therapy exists.
  • Part 2 (single-agent expansion cohort): Subjects with NSCLC, melanoma, HNSCC, G/GEA, RCC, or TCC, with histologically confirmed, locally advanced or metastatic, non-resectable disease, which has progressed despite all standard therapies including CPI or for whom no standard or clinically acceptable therapy exists.
  • Part 4 (expansion cohorts in combination with pembrolizumab, with or without chemotherapy): Subjects with melanoma (all types), HNSCC, G/GEA, RCC, TCC, NSCLC, or MSI-high, TMB-high, MMR-deficient tumors, with histologically confirmed, locally advanced or metastatic, non resectable disease, which is either CPI-naive (melanoma, HNSCC, NPC) or progressed despite all standard therapies including CPI (NSCLC, RCC, TCC, uveal melanoma, MSI-high, TMB-high, or MMR-deficient solid tumors) or for whom no standard or clinically acceptable therapy exists.
  • For Cohort F3 (NSCLC), subjects may have progressed on no more than 2 lines of standard therapy that must include at least one PD-1/L1 regimen.
  • For Cohort F4 (HNSCC and NPC), subjects may be previously treated with no more than 1 prior chemotherapy regimen in metastatic setting. Prior PD-1/L1 in curative (neo-adjuvant/adjuvant) setting is allowed only if completed >/= 6 months prior to progression to local recurrence or metastatic disease.
  • For Cohort F8, subjects must have previously untreated, histologically confirmed Stage II, IIIA or IIIB (T3-4N2) NSCLC. Lymph node disease requires histologic confirmation, while T3 disease requires only radiographic documentation. Subjects need to be able to undergo planned surgery.
  • All subjects with non-squamous NSCLC must have documentation of absence of tumor activating EGFR mutations and absence of ALK gene rearrangements.
  • PD-L1 by IHC (22C3): Parts 1 and 3: IHC optional. Part 2: IHC result mandatory but any score allowed. Combined Positive Score (CPS) ≥ 1% (or Tumor Proportion Score ≥50% for NSCLC; for TMB-high tumors, any TPS% is allowed). Part 4: Combined Positive Score (CPS) ≥ 1% (or Tumor Proportion Score ≥50% for NSCLC; for TMB-high tumors, any TPS% is allowed). For Cohort F8, any TPS (including 0%) is acceptable.
  • Adequate hematologic, coagulation, hepatic and renal function and ECOG score as defined per protocol.

Select Exclusion Criteria:

  • Prior exposure to OX40 agonists. Exposure to anti-PD-1 and/or anti PD-L2 CPIs or an agent targeting other co-stimulatory T-cell receptor pathways.
  • Receipt of any investigational product or any approved anticancer drug(s) or biological product(s) within 4 weeks prior to the first dose of study drug with certain exceptions.
  • Hematologic malignancies (e.g., ALL, AML, MDS, CLL, CML, NHL, Hodgkin's lymphoma and multiple myeloma)
  • Prior or concurrent malignancies. Exception: Subjects with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessments of INBRX-106.
  • Grade ≥ 3 immune-related adverse events (irAEs) or irAE that lead to discontinuation of prior immunotherapy. Some exceptions as defined per protocol apply.
  • Active autoimmune disease or documented history of autoimmune disease that required systemic steroids or other immunosuppressive medications. Certain exceptions as defined in protocol apply.
  • Diagnosis of immunodeficiency or treatment with systemic immunosuppressive medications within 7 days prior to the first dose of study drug. Certain exceptions as defined in protocol apply.
  • History of hepatitis B, hepatitis C, or human immunodeficiency virus (HIV) infection. Exceptions as defined in protocol apply.
  • Active interstitial lung disease (ILD) or pneumonitis or a history of ILD or pneumonitis requiring treatment with steroids or other immunosuppressive medications.
  • Clinically significant cardiac condition, including myocardial infarction, uncontrolled angina, viral myocarditis, cerebrovascular accident, or other acute uncontrolled heart disease < 3 months prior to enrollment on this trial; left ventricular ejection fraction (LVEF) < 50%; New York Heart Association (NYHA) Class III or IV congestive heart failure; or uncontrolled hypertension; or oxygen saturation <92% on room air.
  • Active, hemodynamically significant pulmonary embolism within 12 weeks prior to enrollment on this trial.
  • Major surgery within 4 weeks prior to enrollment on this trial.
  • Anti-infectious drug treatments (i.e., antibiotics) within 4 weeks prior to the first dose of study drug.
  • Prior organ allograft transplantations or allogeneic peripheral blood stem cell (PBSC) or bone marrow (BM) transplantation.
  • Additional in- and exclusion criteria per protocol.

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

  • 主な目的:処理
  • 割り当て:ランダム化
  • 介入モデル:順次割り当て
  • マスキング:独身

武器と介入

参加者グループ / アーム
介入・治療
実験的:Part 1 INBRX-106 Escalation (Not Recruiting)

INBRX-106 will be escalated in subjects with locally advanced or metastatic solid tumors.

The active ingredient of INBRX-106 is a recombinant, humanized, hexavalent IgG antibody that targets the human OX40 receptor (TNFRSF4).

実験的:Part 3 INBRX-106 Escalation in Combination with pembrolizumab (Not Recruiting)

INBRX-106 will be escalated, in combination with pembrolizumab, in subjects with locally advanced or metastatic solid tumors.

The active ingredient of INBRX-106 is a recombinant, humanized, hexavalent IgG antibody that targets the human OX40 receptor (TNFRSF4).

pembrolizumab 200 mg by intravenous (IV) infusion, given on Day 1 of each 21-day cycle.

他の名前:
  • キイトルーダ
実験的:Part 2 (Cohorts C1/C2) INBRX-106 Escalation in Various Solid Tumor Types (Not Recruiting)

Subjects with melanoma (any type), head and neck squamous cell carcinoma, renal cell carcinoma, urothelial carcinoma or MSI/TMB-high tumors that are relapsed or refractory to prior checkpoint inhibitor (CPI) therapy will be treated with INBRX-106

The active ingredient of INBRX-106 is a recombinant, humanized, hexavalent IgG antibody that targets the human OX40 receptor (TNFRSF4).

pembrolizumab 200 mg by intravenous (IV) infusion, given on Day 1 of each 21-day cycle.

他の名前:
  • キイトルーダ
実験的:Part 2 (Cohort C3) INBRX-106 Escalation in NSCLC (Not Recruiting)

Subjects with non-small cell carcinoma relapsed or refractory to prior checkpoint inhibitor (CPI) therapy will be treated with INBRX-106

pembrolizumab 200 mg by intravenous (IV) infusion, given on Day 1 of each 21-day cycle.

他の名前:
  • キイトルーダ
実験的:Part 4 (Cohort F3a) INBRX-106 Expansion in Combination with pembrolizumab in NSCLC (Not Recruiting)

Subjects with non-small cell lung cancer will be treated with alternating dosing of INBRX-106 0.3 mg/kg Q6W and 400 mg pembrolizumab IV Q6W. This is one of the randomized cohorts.

The active ingredient of INBRX-106 is a recombinant, humanized, hexavalent IgG antibody that targets the human OX40 receptor (TNFRSF4).

pembrolizumab 400 mg by IV infusion given on Day 1 of alternating 21-day cycles (every 6 weeks)

他の名前:
  • キイトルーダ
実験的:Part 4 (Cohort F3b) INBRX-106 Expansion in Combination with pembrolizumab in NSCLC (Not Recruiting)

Subjects with non-small cell lung cancer will be given a 0.3 mg/kg priming dose of INBRX-106 in cycle 1, followed by 0.1 mg/kg INBRX-106 and 200 mg pembrolizumab IV every 3 weeks in subsequent cycles. This is one of the randomized cohorts.

The active ingredient of INBRX-106 is a recombinant, humanized, hexavalent IgG antibody that targets the human OX40 receptor (TNFRSF4).

pembrolizumab 200 mg by intravenous (IV) infusion, given on Day 1 of each 21-day cycle.

他の名前:
  • キイトルーダ

pembrolizumab 400 mg by IV infusion given on Day 1 of alternating 21-day cycles (every 6 weeks)

他の名前:
  • キイトルーダ
アクティブコンパレータ:Part 4 (Cohort F3c) Pembrolizumab Expansion Arm (Not Recruiting)

Subjects with non-small cell lung cancer will be treated with 200 mg pembrolizumab IV every 3 weeks. This is one of the randomized cohorts.

The active ingredient of INBRX-106 is a recombinant, humanized, hexavalent IgG antibody that targets the human OX40 receptor (TNFRSF4).

実験的:Part 4 (Cohort F3d) INBRX-106 Expansion in Combination with pembrolizumab in NSCLC (Not-Recruiting)

Subjects with non-small cell lung cancer will be treated concurrently every 6 weeks with INBRX-106 0.1 mg/kg and 200 mg pembrolizumab IV every 3 weeks. This is one of the randomized cohorts.

The active ingredient of INBRX-106 is a recombinant, humanized, hexavalent IgG antibody that targets the human OX40 receptor (TNFRSF4).

実験的:Part 4 (Cohort F4) INBRX-106 Expansion in Combination with pembrolizumab (Not Recruiting)

Subjects with melanoma (any type), head and neck squamous cell carcinoma (non-nasopharyngeal) OR nasopharyngeal carcinoma, MSI-high, TMB-high or MMR-deficient tumors, will be treated with INBRX-106 in combination with 200mg pembrolizumab IV every 3 weeks.

The active ingredient of INBRX-106 is a recombinant, humanized, hexavalent IgG antibody that targets the human OX40 receptor (TNFRSF4).

pembrolizumab 200 mg by intravenous (IV) infusion, given on Day 1 of each 21-day cycle.

他の名前:
  • キイトルーダ
実験的:Part 4 (Cohort F5)INBRX-106 Expansion with pembrolizumab in MSI/TMB-high/MMRd tumors Not Recuriting

Subjects with solid tumors that have confirmed MSI-high, TMB-high or MMR-deficient states who are relapsed or refractory to checkpoint inhibitor (CPI) therapy will be treated with INBRX-106 and 200 mg pembrolizumab IV every 3 weeks

The active ingredient of INBRX-106 is a recombinant, humanized, hexavalent IgG antibody that targets the human OX40 receptor (TNFRSF4).

pembrolizumab 200 mg by intravenous (IV) infusion, given on Day 1 of each 21-day cycle.

他の名前:
  • キイトルーダ
実験的:Part 4 (Cohort F6) INBRX-106 Expansion with pembrolizumab in Uveal Melanoma (Not Recruiting)

Subjects with ocular (uveal) melanoma who are relapsed or refractory to checkpoint inhibitor (CPI) therapy will be treated with INBRX-106 and 200 mg pembrolizumab IV every 3 weeks

The active ingredient of INBRX-106 is a recombinant, humanized, hexavalent IgG antibody that targets the human OX40 receptor (TNFRSF4).

pembrolizumab 200 mg by intravenous (IV) infusion, given on Day 1 of each 21-day cycle.

他の名前:
  • キイトルーダ

carboplatin AUC-5 by intravenous (IV) infusion, given on Day 1 of each 21-day cycle of cycles 1-4. Cohort F8, carboplatin AUC-5 by intravenous (IV) infusion, given on Day 1 of each 21-day cycle of cycle 2-4.

pemetrexed 500 mg/m2 by IV infusion given on Day 1 of each 21-Day cycle for up to 35 cycles. In Cohort F8, pemetrexed 500 mg/m2 by IV infusion given on Day 1 of each 21-Day cycle of cycles 1-4.

他の名前:
  • アリムタ®
実験的:Part 4 (Cohort F7a) INBRX-106 Expansion with pembrolizumab, pemetrexed and carboplatin in NSCLC

This Arm is no longer recruiting. Subjects with advanced/metastatic NSCLC, any PD-L1 TPS will be treated with INBRX-106 0.1mg/kg, 200mg pembrolizumab, 500mg/m2 pemetrexed and carboplatin AUC-5 IV every 3 weeks

The active ingredient of INBRX-106 is a recombinant, humanized, hexavalent IgG antibody that targets the human OX40 receptor (TNFRSF4).

pembrolizumab 200 mg by intravenous (IV) infusion, given on Day 1 of each 21-day cycle.

他の名前:
  • キイトルーダ

pemetrexed 500 mg/m2 by IV infusion given on Day 1 of each 21-Day cycle for up to 35 cycles. In Cohort F8, pemetrexed 500 mg/m2 by IV infusion given on Day 1 of each 21-Day cycle of cycles 1-4.

他の名前:
  • アリムタ®

cisplatin 75mg/m2 by intravenous (IV) infusion, given on Day 1 of each 21-day cycle of cycles 1-4

実験的:Part 4 (Cohort F7b) INBRX-106 Expansion with pembrolizumab, pemetrexed and cisplatin in NSCLC

This Arm is no longer recruiting. Subjects with advanced/metastatic NSCLC, any PD-L1 TPS will be treated with INBRX-106 0.1mg/kg, 200mg pembrolizumab, 500mg/m2 pemetrexed and 75mg/m2 cisplatin IV every 3 weeks

The active ingredient of INBRX-106 is a recombinant, humanized, hexavalent IgG antibody that targets the human OX40 receptor (TNFRSF4).

pembrolizumab 200 mg by intravenous (IV) infusion, given on Day 1 of each 21-day cycle.

他の名前:
  • キイトルーダ

carboplatin AUC-6 by intravenous (IV) infusion, given on Day 1 of each 21-day cycle of cycles 1-4

paclitaxel 200mg/m2 by intravenous (IV) infusion, given on Day 1 of each 21-day cycle of cycles 1-4

Nab paclitaxel 100mg/m2 by intravenous (IV) infusion, given on Days 1, 8 and 15 of each 21-day cycle of cycles 1-4

実験的:Part 4(Cohort F7c)INBRX-106 Expansion with pembrolizumab, (Nab)-paclitaxel and carboplatin in NSCLC

This Arm is no longer recruiting. Subjects with advanced/metastatic NSCLC, any PD-L1 TPS will be treated with INBRX-106 0.1mg/kg, 200mg pembrolizumab, 200mg/m2 paclitaxel and carboplatin AUC-6 IV every 3 weeks OR INBRX-106, 200mg pembrolizumab, 100mg/m2 nab-paclitaxel (dosed Days 1,8 and 15 every cycle) and carboplatin AUC-6 IV every 3 weeks. Treating physician to determine if paclitaxel or nab-paclitaxel will be given

The active ingredient of INBRX-106 is a recombinant, humanized, hexavalent IgG antibody that targets the human OX40 receptor (TNFRSF4).

pembrolizumab 200 mg by intravenous (IV) infusion, given on Day 1 of each 21-day cycle.

他の名前:
  • キイトルーダ
実験的:Part 4(Cohort F8)INBRX-106 with pembrolizumab, cisplatin and gemcitabine or pemetrexed in NSCLC

Subjects with resectable Stage II, IIIA or IIIB (T3-4N2) NSCLC , any PD-L1 TPS will receive neoadjuvant treatment with INBRX-106 0.1 mg/kg, 200 mg pembrolizumab, cisplatin 75 mg/m2 (dosed Day 1 only) with gemcitabine 1000 mg/m2 (dosed on Days 1 and 8) for patients with squamous cell NSCLC given every 3 weeks OR neoadjuvant treatment with INBRX-106 0.1 mg/kg, 200 mg pembrolizumab, cisplatin 75 mg/m2 with pemetrexed 500 mg/m2 for patients with non-squamous cell NSCLC given every 3 weeks. Carboplatin AUC5 (dosed on Day 1 only) can be substituted for Cisplatin for subjects who are clinically considered ineligible or unsuitable for cisplatin per the Investigator's discretion or institution SOPs. Neoadjuvant treatment will be given for up to 4 cycles followed by surgery (lobectomy, bilobectomy or pneumonectomy). After surgery, all patients will receive adjuvant treatment consisting of INBRX-106 0.1 mg/kg, 200 mg pembrolizumab given every 3 weeks for up to 13 cycles.

The active ingredient of INBRX-106 is a recombinant, humanized, hexavalent IgG antibody that targets the human OX40 receptor (TNFRSF4).

pembrolizumab 200 mg by intravenous (IV) infusion, given on Day 1 of each 21-day cycle.

他の名前:
  • キイトルーダ

carboplatin AUC-5 by intravenous (IV) infusion, given on Day 1 of each 21-day cycle of cycles 1-4. Cohort F8, carboplatin AUC-5 by intravenous (IV) infusion, given on Day 1 of each 21-day cycle of cycle 2-4.

pemetrexed 500 mg/m2 by IV infusion given on Day 1 of each 21-Day cycle for up to 35 cycles. In Cohort F8, pemetrexed 500 mg/m2 by IV infusion given on Day 1 of each 21-Day cycle of cycles 1-4.

他の名前:
  • アリムタ®

cisplatin 75mg/m2 by intravenous (IV) infusion, given on Day 1 of each 21-day cycle of cycles 1-4

Gemcitabine 1000 mg/m2 given by intravenous (IV) infusion on Days 1 and 8 of each 21-day cycle of cycles 1-4

この研究は何を測定していますか?

主要な結果の測定

結果測定
メジャーの説明
時間枠
Frequency of adverse events of INBRX-106 as single agent and in combination with pembrolizumab
時間枠:~2 years

Adverse events will be assessed by the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE), version 5.0

~2 years
Severity of adverse events of INBRX-106 as single agent and in combination with pembrolizumab
時間枠:~2 years

Adverse events will be assessed by the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE), version 5.0

~2 years
MTD and/or RP2D of INBRX-106 as single agent and in combination with pembrolizumab
時間枠:~2 years

Maximum Tolerated Dose (MTD) and/or Recommended Phase 2 Dose (RP2D) of INBRX-106 and INBRX-106 in combination with pembrolizumab

~2 years
Antitumor activity of INBRX-106 in combination with pembrolizumab in expansion cohorts
時間枠:~2 years

The evaluation of efficacy will be based on the subject's measurable disease using RECIST v1.1

~2 years
Frequency and severity of adverse events of INBRX-106 in combination with pembrolizumab and chemotherapy in adults with locally advanced or metastatic NSCLC or resectable Stage II, IIIA or IIIB (T3-4N2) NSCLC
時間枠:~2 years

Adverse events will be assessed by the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE), version 5.0

~2 years
To assess the antitumor activity of INBRX-106 in combination with pembrolizumab and platinum doublet chemotherapy as neoadjuvant/adjuvant therapy in adult subjects with NSCLC. (Cohort F8)
時間枠:~2 years

Major pathological response (mPR) and pathological complete response (cPR) criteria.

~2 years

二次結果の測定

結果測定
メジャーの説明
時間枠
Area under the serum concentration time curve (AUC) of INBRX-106
時間枠:~2 years

Area under the serum concentration time curve (AUC) of INBRX-106 as a single agent and in combination with pembrolizumab with or without chemotherapy will be determined.

~2 years
Maximum observed serum concentration (Cmax) of INBRX-106
時間枠:~2 years

Maximum observed serum concentration (Cmax) of INBRX-106 as a single agent and in combination with pembrolizumab with or without chemotherapy will be determined.

~2 years
Trough observed serum concentration (Ctrough) of INBRX-106
時間枠:~2 years

Trough observed serum concentration (Ctrough) of INBRX-106 as a single agent and in combination with pembrolizumab with or without chemotherapy will be determined.

~2 years
Time to Cmax (Tmax) of INBRX-106
時間枠:~2 years

Time to Cmax (Tmax) of INBRX-106 as a single agent and in combination with pembrolizumab with or without chemotherapy will be determined.

~2 years
Immunogenicity of INBRX-106
時間枠:~2 years

Frequency of anti-drug antibodies (ADA) against INBRX-106 as a single agent and in combination with pembrolizumab with or without chemotherapy will be determined.

~2 years

その他の成果指標

結果測定
メジャーの説明
時間枠
Anti-tumor activity of INBRX-106 as single agent and in combination with pembrolizumab with or without chemotherapy
時間枠:~2 years

Tumor response will be determined by the revised Response Evaluation Criteria in Solid Tumors version 1.1 (RECISTv1.1).

~2 years
Anti-tumor activity of INBRX-106 as single agent and in combination with pembrolizumab with or without chemotherapy
時間枠:~2 years

Tumor response will be determined by Response Evaluation Criteria in Solid Tumors (RECIST v1.1).

~2 years

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

スポンサー

捜査官

  • スタディディレクター:Clinical Lead、Inhibrx Biosciences, Inc

出版物と役立つリンク

研究に関する情報を入力する責任者は、自発的にこれらの出版物を提供します。これらは、研究に関連するあらゆるものに関するものである可能性があります。

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (実際)

2019年12月10日

一次修了 (推定)

2033年7月1日

研究の完了 (推定)

2033年7月1日

試験登録日

最初に提出

2019年12月11日

QC基準を満たした最初の提出物

2019年12月11日

最初の投稿 (実際)

2019年12月13日

学習記録の更新

投稿された最後の更新 (実際)

2026年11月6日

QC基準を満たした最後の更新が送信されました

2026年11月4日

最終確認日

2026年11月1日

詳しくは

本研究に関する用語

追加の関連 MeSH 用語

その他の研究ID番号

  • Ph 1 Ph 2 INBRX-106
  • KEYNOTE A99 and MK-3475-A99 (その他の識別子:Merck Sharp & Dohme LLC)

個々の参加者データ (IPD) の計画

個々の参加者データ (IPD) を共有する予定はありますか?

いいえ

医薬品およびデバイス情報、研究文書

米国FDA規制医薬品の研究

はい

米国FDA規制機器製品の研究

いいえ

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。

購読する